GHISLAINE KENMEGNE DATOUO MOGO
Prescription History 1164064705
Nurse Practitioner - Psychiatric/Mental Health in Washington, DC

NPI Status: Active since October 15, 2019

Contact Information

4130 HUNT PL NE
WASHINGTON, DC
ZIP 20019
Phone: (202) 679-0620

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for GHISLAINE KENMEGNE DATOUO MOGO, an active Psychiatric/Mental Health specialist practicing in Washington, DC. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 37 documented patient claims. Among these therapy options, the most frequently utilized medication is Hydroxyzine Pamoate, which accounts for 13 claims alone.

Medication Index

No matching medications currently found on file.

Hydroxyzine Pamoate

Generic Formulation: Hydroxyzine PamoateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 13
30-Day Fills 15.0
Days Supply 420
DC State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills33.5
Peer Average Days Supply932
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.6% less volume than the regional standard for practitioners inside DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $332.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$25.55

State Avg Cost Per Claim

$14.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.

Therapeutic Applications

Hydroxyzine is used to treat itching caused by allergies. It is an antihistamine and works by blocking a certain natural substance (histamine) that your body makes during an allergic reaction. Hydroxyzine may also be used short-term to treat anxiety or to help you feel sleepy/relaxed before and after surgery.

Lurasidone Hcl

Generic Formulation: Lurasidone HclSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
DC State Average Benchmarks
Peer Average Claims--
Peer Average 30-Day Fills--
Peer Average Days Supply--

Provider Avg Cost Per Claim

$249.48

State Avg Cost Per Claim

--

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Mirtazapine

Generic Formulation: MirtazapineSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 12
30-Day Fills 17.0
Days Supply 510
DC State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills57.1
Peer Average Days Supply1,542
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 69.2% less volume than the regional standard for practitioners inside DC. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $243.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.26

State Avg Cost Per Claim

$26.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.

Therapeutic Applications

Mirtazapine is used to treat depression. It improves mood and feelings of well-being. Mirtazapine is an antidepressant that works by restoring the balance of natural chemicals (neurotransmitters) in the brain.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like GHISLAINE KENMEGNE DATOUO MOGO provides transparency into local medical care patterns within Washington, DC.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Psychiatric/Mental Health** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.